BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33351823)

  • 21. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
    Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
    Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
    Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Adherence to Renin-Angiotensin System Inhibitors and β-Blockers After Heart Failure Hospitalization in Senior Patients.
    Qin X; Hung J; Teng TK; Briffa T; Sanfilippo FM
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):531-540. PubMed ID: 32500739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans' Health Administrative Database.
    Mathew RO; Lo KB; Tipparaju P; Phelps E; Sidhu MS; Bangalore S; Herzog C; Vaduganathan M; Tang WHW; Rangaswami J
    Cardiorenal Med; 2021; 11(5-6):226-236. PubMed ID: 34601469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
    Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
    Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
    Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
    Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
    Wirtz HS; Sheer R; Honarpour N; Casebeer AW; Simmons JD; Kurtz CE; Pasquale MK; Globe G
    J Am Heart Assoc; 2020 Aug; 9(16):e015042. PubMed ID: 32805181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.
    Bertero E; Miceli R; Lorenzoni A; Balbi M; Ghigliotti G; Chiarella F; Brunelli C; Viazzi F; Pontremoli R; Canepa M; Ameri P
    Intern Emerg Med; 2019 Oct; 14(7):1083-1090. PubMed ID: 30835055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-based pharmacotherapies used in the postdischarge phase are associated with improved one-year survival in senior patients hospitalized with heart failure.
    Qin X; Hung J; Knuiman M; Teng TK; Briffa T; Sanfilippo FM
    Cardiovasc Ther; 2018 Dec; 36(6):e12464. PubMed ID: 30126048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence and Discontinuation of Optimal Heart Failure Therapies According to Age: A Danish Nationwide Study.
    Garred CH; Zahir D; Butt JH; Ravn PB; Bruhn J; Gislason GH; Fosbøl EL; Torp-Pedersen C; Petrie MC; McMurray JJV; Køber L; Schou M
    J Am Heart Assoc; 2022 Oct; 11(19):e026187. PubMed ID: 36172925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing Baseline Metrics of Heart Failure Medication Use in Children: A Collaborative Effort from the ACTION Network.
    Stidham J; Feingold B; Almond CS; Burstein DS; Krack P; Price JF; Schumacher KR; Spinner JA; Rosenthal DN; Lorts A; Godown J
    Pediatr Cardiol; 2021 Feb; 42(2):315-323. PubMed ID: 33044586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
    Vaduganathan M; Greene SJ; Zhang S; Solomon N; Chiswell K; Devore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Mcdermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
    J Card Fail; 2022 Apr; 28(4):554-563. PubMed ID: 34785402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry.
    Yoshikawa Y; Tamaki Y; Morimoto T; Yaku H; Yamamoto E; Inuzuka Y; Ozasa N; Kitai T; Nagao K; Sato Y; Kondo H; Tamura T; Nakagawa Y; Kuwahara K; Kato T; Kimura T
    PLoS One; 2020; 15(9):e0239100. PubMed ID: 32925953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization.
    Sim HW; Zheng H; Richards AM; Chen RW; Sahlen A; Yeo KK; Tan JW; Chua T; Tan HC; Yeo TC; Ho HH; Liew BW; Foo LL; Lee CH; Hausenloy DJ; Chan MY
    Sci Rep; 2020 Sep; 10(1):15184. PubMed ID: 32938986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials.
    Vader JM; LaRue SJ; Stevens SR; Mentz RJ; DeVore AD; Lala A; Groarke JD; AbouEzzeddine OF; Dunlay SM; Grodin JL; Dávila-Román VG; de Las Fuentes L
    J Card Fail; 2016 Nov; 22(11):875-883. PubMed ID: 27133201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.